SAN DIEGO, April 15, 2019 – ProSciento, Inc., a clinical research organization (CRO) exclusively focused on metabolic diseases, will present scientific data at the 3rd Annual NASH Summit in Boston, April 22-25. ProSciento’s Chief Medical Officer, Dr. Linda Morrow, will also present at the Summit’s morning plenary session on Wednesday, April 24.
Dr. Morrow’s plenary presentation, titled “NASH/NAFLD: Does Genotype Connect to Phenotype,” will discuss genetic markers and their impact on individualized medicine for NASH/NAFLD patients.
The poster presentation, titled “Comparison of controlled attenuation parameter and MRI-PDFF for the assessment of hepatic steatosis in subjects at high risk for nonalcoholic fatty liver disease (NAFLD),” analyzes CAP and MRI-PDFF hepatic steatosis measurements in a phase 1 study and evaluates the utility of CAP to pre-identify subjects likely to have fatty liver.
About the NASH Summit
Now in its 3rd year, the NASH Summit in Boston is a forum for advancing the development of successful NASH therapeutics. Focused on discovery through to late-stage clinical development of NASH candidate pipelines, the 3rd Annual NASH Summit will bring together 300+ drug developers from 140+ organizations across four days of content sharing and networking.
About ProSciento, Inc.
ProSciento is a leading specialized clinical research organization (CRO) exclusively focused on NASH, diabetes, obesity and related metabolic diseases. ProSciento works with biopharma companies worldwide to support their outsourced clinical research needs with comprehensive and customized services for multinational, early development clinical trial programs. Founded in 2003, ProSciento has conducted more than 280 clinical projects for diabetes, NASH and obesity and supported the development of many approved metabolic drugs and devices on the market globally. For more information, please visit www.prosciento.com.
To inquire about a meeting with Dr. Morrow during the NASH Summit, please contact email@example.com.
For all other inquiries, please contact:
Senior Director, Corporate Communications, ProSciento, Inc.